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Key points 
- MiR-125b induces tumorigenesis in myeloid cells by repressing the expression of IRF4 at 
the mRNA and protein level 
- MiR-125b promotes oncogenesis in B cells that involves selection of cells that acquire 
genetic deletion of the gene encoding IRF4 
 
Abstract 
The oncomir microRNA-125b (miR-125b) is up-regulated in a variety of human 
neoplastic blood disorders and constitutive up-regulation of miR-125b in mice can promote 
myeloid and B cell leukemia. We found that miR-125b promotes myeloid and B cell neoplasm 
by inducing tumorigenesis in hematopoietic progenitor cells. Our study demonstrates that miR-
125b induces myeloid leukemia by enhancing myeloid progenitor output from stem cells as well 
as inducing immortality, self-renewal, and tumorigenesis in myeloid progenitors. Through 
functional and genetic analyses, we demonstrated that miR-125b induces myeloid and B cell 
leukemia by inhibiting IRF4 but through distinct mechanisms; it induces myeloid leukemia 
through repressing IRF4 at the mRNA level without altering the genomic DNA and induces B 
cell leukemia via genetic deletion of the gene encoding IRF4.  
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 Introduction  
 MicroRNAs have been found to be dysregulated in several types of human and mouse 
cancers, including carcinomas and leukemias. As happens with protein-coding oncogenes, non-
coding oncomirs can provoke cancers by dysregulating developmental, signaling and cell 
survival pathways in different cell types. For the majority of oncomirs, it is not clear how a single 
microRNA can induce cancer development in various cell types. Potentially, an oncomir can 
suppress the same target(s) in different cell types to promote tumorigenesis, or it can inhibit 
distinct cell-specific targets to induce cancer development.    
The oncomir microRNA-125b (miR-125b) is up-regulated in a myriad of neoplastic blood 
disorders, including acute myeloid leukemia (AML) and B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) [1-3]. Importantly, we and other researchers showed that enforced 
constitutive over-expression of miR-125b in mice induces myeloid, B cell, and T cell leukemia 
[4-7], indicating that miR-125b can provoke the oncogenic state in a range of hematopoietic 
cells. Interestingly, we found that miR-125b over-expression initially impairs the development of 
B cells whereas others found that it induces B cell leukemia [5, 6]. This suggests that miR-125b 
might initially repress the development of B cells but that these cells might acquire secondary 
mutational or epigenetic events that transform them into cancer cells. To date, the mechanism 
by which miR-125b induces tumorigenesis in different hematopoietic lineages is unknown.  
Previously, we found that down-regulating the expression of the direct miR-125b target 
IRF4 was sufficient to recapitulate the activated phenotype observed upon over-expressing 
miR-125b in bone marrow-derived macrophages [8]. Relevant to leukemia, the expression of 
Irf4 is down-regulated in a range of hematopoietic cancer cell lines [9] as well as in human 
patients with AML, chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL) 
[10, 11]. Also, deletion of IRF4 in mice exacerbates the development of myeloid leukemia and 
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 leads to development of B cell leukemia [12-14]. However, whether repression of IRF4 plays a 
functional role in miR-125b-induced myeloid and B cell leukemia remains to be tested.    
In this study, we have investigated the cellular and molecular mechanisms by which 
miR-125b induces the development of myeloid and B cell leukemia. We found that miR-125b 
induces cancer development by initiating tumorigenesis in myeloid and B precursor cells. Our 
data also indicates that in both cases miR-125b induces myeloid and B cell leukemia by 
inhibiting IRF4 expression. Whereas miR-125b induces tumorigenesis in myeloid cells by 
repressing the expression of IRF4 at the mRNA and protein level, it promotes oncogenesis in B 
cells by provoking genetic deletion of IRF4. Thus, miR-125b represents a novel paradigm by 
which an oncomir induces cancer development in multiple cell lineages by modulating the same 
signaling pathway but via distinct mechanisms.   
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 Methods 
 
DNA Constructs 
pMG, pMSCV-IRES-GFP (MIG), pMG-miR-125b, and pMiR-report IRF4 3’UTR vectors have 
been described [5, 8]. pMIG-miR-125b co-expresses GFP and miR-125b.  pMIG-IRF4 co-
expresses GFP and IRF4. pHcRed-miR125b and pmCherry-miR125b co-express miR-125b and 
HcRed or mCherry, respectively (Supp. Table 1 for cloning primers). 
 
Infection of BMCs, bone marrow reconstitution, and in vitro cell proliferation assays 
To generate MG and MG-125b mice, lethally irradiated C57bl/6 recipient mice were injected 
with virally transduced bone marrow cells (BMCs).  Briefly, donor C57bl/6 BMCs were 
transduced with miR-125b over-expressing vector (pMG-miR-125b or pMIG-miR-125b) through 
two to four rounds of spin infection, which achieved 25- and 186-fold higher miR-125b over-
expression (Supp. Fig. S7).  The expression levels are within range of the level of miR-125b 
over-expression observed in human patients with leukemia or myelodysplastic syndromes, 
which range from several to 262-fold above normal [1, 6, 15].  For the in vitro proliferation 
assays, BMCs and sorted Lin- cKit+ Sca1- MPs were cultured and passaged in 50ng/mL SCF, 
and sorted Lin- cKit+ Sca1+ HSPCs were cultured in media containing 50ng/mL SCF, 50ng/mL 
IL6, and 25ng/mL IL3. All animal studies were approved by the IACUC. 
 
Transplantation of miR-125b-induced cancer cells and fluorescent activated cell sorting 
Splenic cells, BMCs, sorted GFP+ Lin-cKit+Sca1- cells, and sorted GFP+ CD19+ cells were 
harvested from MG-125b mice when they developed leukemia and transplanted into sublethally 
irradiated C57bl/6 recipients.  For transplantation of common myeloid progenitors, 3.5K Lin-
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 cKit+Sca1- cells (Lin = ILR7a, Thy1, Cd11b, Cd11c, B220, Ter119, CD3e, NK1.1, GR-1) were 
sorted from MG-125b mice when they were moribund.  Cells were sorted using the FACSAria 
(BD Biosciences) or iCyte (Sony Biotech) instrument.  Flow cytometric antibodies were 
purchased from eBioscience or Biolegend.  
 
Single cell analysis and cell differentiation assay 
MiR-125b over-expressing Lin- cKit+ Sca1- MPs were passaged six times in 50ng/mL SCF 
media. Single cells were plated. One month later, an aliquot of the expanded cells were 
assayed for granulocytes formation and some cells were cultured in 20ng/mL MCSF or J558L-
GMCSF conditioned media to differentiate into macrophages and dendritic cells, respectively.   
 
In vitro proliferation assay with rescued expression of IRF4  
For in vitro proliferation assays, BMCs were first infected with pHcRed-miR-125b retroviruses 
that express miR-125b and HcRed. Subsequently, cells were infected with pMIG or pMIG-IRF4 
retroviruses. HcRed+ GFP+ cells were sorted and cultured in 50ng/mL SCF.  
 
Competitive repopulation of miR-125b over-expressing cells with rescued IRF4 
expression. 
Donor BMCs were infected with mCherry+ miR-125b over-expressing virus (pmCherry-miR-
125b vector). The cells were then infected with GFP+ virus (pMIG vector) or GFP+ IRF4 over-
expressing virus (pMIG-IRF4 vector) and transplanted into irradiated C57bl/6 mice.  
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 Transplantation of sorted miR-125b over-expressing cells with restored IRF4 expression 
BMCs were infected with GFP+ miR-125b over-expressing retroviruses (pMG-miR-125b vector) 
or co-infected with HcRed+ miR-125b over-expressing (pHcRed-miR-125b vector) and GFP+ 
IRF4 over-expressing retroviruses (pMIG-IRF4 vector). GFP+ cells or GFP+ HcRed+ cells were 
sorted from the former and latter group of cells, respectively. The sorted BMCs were 
transplanted into irradiated C57bl/6 mice.  
 
Exome sequencing and comparative genomic hybridization microarray (aCGH) 
See supplemental methods for detailed experimental setup and data analysis. The microarray 
GEO accession number is: GSE58900. 
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 Results  
 
MiR-125b over-expressing leukemic cells are serially transplantable  
To examine the ability of miR-125b-induced myeloid cancer cells to serially propagate, 
we over-expressed miR-125b through bone-marrow reconstitution experiments using the 
MSCV-GFP+ (MG)-based retroviral system in mice (hereon denoted as ‘MG-125b’) [5].  When 
the MG-125b mice developed frank myeloid leukemia, cells from the spleen or bone marrow 
were transferred into sub-lethally irradiated secondary recipients. These recipients were 
moribund or died within 70 days (Fig. 1A) and developed leukemia indicated by increased white 
blood cell count (Fig. S1A) and splenomegaly (Fig. S1B). Recipient mice that received cells 
from control ‘MG’ mice did not develop cancer and remained healthy through the duration of the 
study (Fig. 1A). Remarkably, transplantation of miR-125b-induced cancer cells from secondary 
recipients into tertiary non-irradiated immuno-competent recipients also induced myeloid 
leukemia in the mice (Fig. 1A, Fig. S1C-D). Collectively, our data indicates that the myeloid 
cancer induced by miR-125b over-expression is serially transplantable.  
 
Genetic analyses of miR-125b myeloid cancer 
Using deep-sequencing technologies, it has been determined that cancer cells can 
acquire few to thousands of secondary mutations in their exomes [16-20].  Thus, we sorted 
GFP+ Cd11b+ myeloid cancer cells induced by miR-125b over-expression and subjected them to 
exome deep-sequencing analysis.  The first sample (sample #1) was harvested from a mouse 
two months after bone marrow reconstitution, which we validated as cancerous cells as 
demonstrated by the ability of these cells to be transplanted into a non-irradiated recipient 
mouse (data not shown).  The second sample (sample #2) was harvested from a miR-125b 
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 over-expressing mouse three months after reconstitution; this mouse developed frank myeloid 
leukemia as characterized by moribund feature, exacerbated myeloid cell count in the blood 
(27x higher than normal), and splenomegaly (data not shown).  The third sample (sample #3) 
was harvested from miR-125b-induced myeloid leukemic cells that were serially transplanted 
into recipient mice to ensure that we were analyzing cancerous cells in our deep-sequencing 
analysis.  The deep-sequencing data sets were filtered based on a 0.1% false discovery rate, 
and cancer-specific mutations were obtained by subtracting those that were also identified in 
normal healthy mice. From the three independent experiments, we identified two, four, and 
thirty-two mutations from samples #1, #2, and #3, respectively (Fig. 1B, Supp. Table 2).  The 
variations in the number of mutations from the different samples might be due to the different 
time at which they were harvest after bone marrow reconstitution.  We have not ruled out the 
possibility that a small fraction of the myeloid cancer cells might have random mutations, which 
is outside of the deep-sequencing detection limit.  However, our data suggests that the majority 
of miR-125b-driven myeloid cancer cell populations in the samples tested have relatively few 
nucleotide mutations in the coding regions and do not have widespread genomic instability.  
 
Over-expression of miR-125b in primary BMCs in vitro recapitulates myeloid malignancy 
phenotype  
 Previously, we showed that induction of myeloid leukemia in mice deleted of the gene for 
a different microRNA, miR-146a, was in part dependent on extrinsic factors released by miR-
146a-/- lymphocytes [21]. Thus, we investigated whether miR-125b over-expressing lymphocytes 
contribute to myeloid cancer development in MG-125b mice.  BMCs harvested from B cell-
deficient EμMT [22] or lymphocyte-deficient Rag1-/- [23] donor mice were transduced with miR-
125b encoding retroviruses and transplanted into normal C57bl/6 recipient mice. These 
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 recipient mice developed myeloid leukemia (Fig. 1C) at a similar time scale and rate (100%) 
compared to those transplanted with miR-125b over-expressing WT BMCs (Fig. 1D), indicating 
that the development of myeloid leukemia provoked by miR-125b does not require miR-125b 
over-expressing lymphocytes.  
Next, we tested whether over-expressing miR-125b in BMCs in vitro could induce 
cellular hyper-proliferation and recapitulate the myeloproliferative phenotype observed in mice.  
We over-expressed miR-125b in BMCs and cultured them in cytokine-supplemented media 
(SCF+IL3+IL6, SCF+IL-3 or SCF+IL-6) that supports growth and differentiation of HSCs, 
myeloid progenitors, and mature myeloid cells. Indeed, over-expression of miR-125b in vitro 
elevated the growth rate of BMCs (Fig. S2A-C) and induced hyper-expansion of myeloid cells 
(Fig. 2A).  MiR-125b over-expressing BMCs cultured in SCF alone, which supports growth of 
hematopoietic stem and progenitor cells, also grew faster (Fig. 2B), suggesting that miR-125b 
induces hyper-proliferation in part due to its effect in stem/progenitor cells. Indeed, growth of 
BMCs with ectopic miR-125b expression generated higher number of Lin- cKit+ Sca1- cells (Fig. 
2C).  In normal counterparts, Lin- cKit+ Sca1- cells represent myeloid progenitors/MPs.  
Consistently with elevated number of myeloid progenitors, miR-125b over-expressing BMCs 
generated more dendritic cells when subjected to a methylcellulose-based colony-forming assay 
(Fig. S2D) or differentiated into dendritic cells in liquid culture (Fig. 2D).  MiR-125b over-
expressing cells also formed more colonies in methylcellulose assay when cultured in present of 
SCF+IL3+IL6 (Fig. S2E) although the cells did not serially re-plate (data not shown).  Thus, our 
in vitro assay recapitulated the phenotype observed with over-expressing miR-125b in mice with 
higher numbers of myeloid progenitors and differentiated Cd11b+ myeloid cells [5]. 
 Moreover, we investigated whether miR-125b over-expression is also sufficient to 
transform and immortalize BMCs in vitro.  Indeed, whereas control cells died after several 
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 passages, miR-125b over-expressing cells continued to grow indefinitely (Fig. 2E). When we 
injected miR-125b over-expressing BMCs that had been cultured in vitro into sublethally 
irradiated recipient mice, the cells dominated the blood of these mice and produced myeloid 
leukemia (Fig. 2F) marked by splenomegaly (Fig. 2G) and bone marrow pallor (Fig 2H). These 
data suggest that the cultured miR-125b over-expressing BMCs were transformed in vitro into 
cancer cells capable of inducing malignancy in vivo.  
 
Effect of over-expressing miR-125b in hematopoietic stem and progenitor cells  
Next, we tested whether miR-125b over-expression elevates the myeloid progenitor pool 
by enhancing the hematopoietic output of cells upstream of MPs, such as hematopoietic stem 
and progenitor cells (HSPCs).  We cultured sorted MG and miR-125b Lin-cKit+Sca1+ (LKS+) 
cells (Fig. S3A) and found that those with miR-125b-over-expression generated higher number 
of cells overall (Fig. 3A) with a moderate increase in absolute LKS+ cell numbers (Fig. 3B) after 
six days of growth. When we instead looked at the Lin-cKit+Sca1- (LKS-) population, the cellular 
output was dramatically higher in the miR-125b over-expressing samples (Fig. 3C) with 
exaggerated ratio of LKS- to LKS+ cells (Fig. 3D). Overall, our data suggests that miR-125b 
functions in HSPCs and increases the output of downstream MPs.  Next, we tested whether 
miR-125b also functions intrinsically in MPs to accelerate the proliferation of these cells.  We 
cultured LKS- cells sorted from BMCs transduced with MG or miR-125b encoding retroviruses. 
We found that the cells with ectopic miR-125b expression grew much faster (Fig. 3E) and 
generated more myeloid cells (Cd11b+) of both granulocytic (GR1+) and non-granulocytic 
lineages (Cd11b+ GR1-) (Fig. 3F).  In addition, the miR-125b-overexpressing cells were also 
more resistant to cell death as indicated by propidium iodide staining (Fig. S3B).  Thus, miR-
125b induces hyper-proliferation and resistance to cell death of MPs in vitro.  
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 Moreover, we found that whereas control LKS- cells died after several passages, miR-
125b over-expressing cells continued to grow indefinitely, suggesting that miR-125b MPs were 
immortalized (Fig. 3G). We also tested whether cultured miR-125b over-expressing LKS- retain 
their ability to differentiate and whether a single cell can re-populate the myeloid repertoire. After 
passaging miR-125b-over-expressing MPs six times, single cells were plated into individual 
wells.  Of the 96 single cells plated, 11 clones expanded beyond one month and were able 
differentiate into GR1+ granulocytes, F4/80+ macrophages, and Cd11c+ dendritic cells (Fig. 
S3C). Collectively, this data indicates that miR-125b over-expression induces self-renewal of 
MPs in vitro.  
To test whether miR-125b over-expression induces tumorigenesis in myeloid 
progenitors, we transplanted sorted MPs from MG-125b mice into sublethally irradiated C57bl/6 
recipients. Indeed, the recipient mice were moribund within 70 days and developed frank 
myeloid leukemia characterized by large excess of myeloid and myeloblast cells in the 
peripheral blood (Fig. 3H), splenomegaly (Fig. 3I) and bone marrow pallor (Fig. 3J), and 
dissemination of cancer cells into non-lymphoid tissues (liver, lung, kidney) (data not shown). In 
further support that miR-125b induces myeloid leukemia through progenitor cells, injection of 
terminally differentiated miR-125b over-expressing dendritic cells into mice did not induce 
leukemia (Fig. S3D-F), indicating the requirement of progenitor state for miR-125b to initiate 
tumorigenesis.  
 
IRF4 expression rescues miR-125b-induced myeloid leukemia 
 Next, we investigated signaling pathways regulated by miR-125b to induce cancer 
development. Previously, we and other labs showed that miR-125b directly inhibits the 
expression of the transcription factor IRF4 [8, 24, 25]. We first confirmed that miR-125b inhibits 
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 IRF4 expression in primary mouse sorted LKS+ and LKS- cells (Fig. S4A-B) and represses a 
luciferase reporter linked to the 3’UTR of IRF4 (Fig. S4C). Next, we tested and found that re-
introduction of IRF4 without its 3’UTR (Fig. S4D-E) into miR-125b-over-expressing BMCs was 
sufficient to reverse the hyper-proliferative phenotype induced by miR-125b (Fig. 4A) and 
prevented miR-125b-mediated myeloid expansion in vitro (Fig. S4F).   
Moreover, we tested the effect of uncontrolled IRF4 expression on miR-125b-over-
expressing mice. To this end, we retrovirally transduced BMCs with a mCherry+ miR-125b-over-
expressing vector and then co-infected these cells with retroviruses expressing both GFP and 
IRF4 (lacking its UTR) or with GFP controls (Fig. 4B). These unsorted retrovirally transduced 
BMCs were then transplanted into C57Bl/6 recipient animals. After reconstitution, we found that 
mice transplanted with cells co-infected with IRF4-GFP and miR125b-mCherry vectors were 
deficient of cells expressing both miR-125b and IRF4 (mCherry+GFP+ population) (Fig. 4C, Fig. 
S4G). They did, however, have a prominent population of mCherry+GFP- cells (Fig. 4C), 
demonstrating that the cells that persisted in these mice were those expressing only miR-125b 
but not ones co-expressing IRF4. In contrast, recipient mice transplanted with cells transduced 
with 125b-mCherry and GFP control vector contained prominent amounts of mCherry+GFP+ 
cells (Fig. 4C, Fig. S4G). Collectively, our data indicates that hematopoietic cells that over-
express miR-125b alone robustly outcompete those with uncontrolled expression of IRF4, 
suggesting that IRF4 inhibits the enhanced proliferative capacity induced by miR-125b in vivo. 
Finally, we examined whether rescued expression of IRF4 could inhibit myeloid leukemia 
provoked by miR-125b over-expression in mice. To this end, we transplanted into recipient mice 
GFP+ BMCs that over-express miR-125b alone or along with restored IRF4 expression.  Both 
populations of BMCs engrafted in the recipients as demonstrated by GFP positivity in the blood 
of these mice.  Whereas the recipient mice transplanted with the former group of cells exhibited 
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 severe myeloid hyperplasia after three months, the animals that received cells with restored 
IRF4 expression had normal myeloid counts (Fig. 4D). As expected, the mice transplanted with 
miR-125b over-expressing cells had exaggerated development of myeloid in their spleens (Fig. 
4E) accompanied by bone marrow pallor (Fig. 4F), which are pathognomonic features of miR-
125b-mediated myeloid leukemia, while those with restored IRF4 expression had normal splenic 
myeloipoiesis and displayed normal reddish bone marrow (Fig. 4E-F). Collectively, our data 
indicates that suppression of IRF4 is important for miR-125b to induce myeloid leukemia and 
restoration of IRF4 can inhibit disease development.   
 
MiR-125b over-expression induces B cell cancer harboring IRF4 deletion 
 We confirmed our previous finding that MG-125b mice have impaired B cell development 
(Fig. 5A) [5]. Curiously, others have shown that B cell-restricted over-expression of miR-125b 
induces lymphoblastic leukemia in mice [6]. We posited that our experimental mice might be 
dying from complications associated with myeloid leukemia before manifesting features of B cell 
leukemia. To examine whether miR-125b promotes B cell leukemia in our experimental setting, 
we sorted the few GFP+ CD19+ B cells from MG-125b mice when they developed myeloid 
leukemia and transplanted these B cells into C57bl/6 recipients. The cells were able to engraft 
in the secondary recipients (Fig. 5B) and proved lethal within two months, generating a 
fulminant CD19+ cancer (Fig. 5C).  Moreover, the resultant GFP+ CD19+ cancer cells were 
serially transplantable into sublethally irradiated or non-irradiated recipient mice for up to 11 
generations (Fig. S5A), inducing B cell leukemia (Fig. 5D) and in some cases B cell lymphoma 
(Fig. 5E) in the recipients. The development of B cell leukemia in these mice was also marked 
by splenomegaly (Fig. 5F) and dissemination of GFP+ CD19+ into non-hematopoietic organs, 
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 including the lung, liver, and kidney (Fig. S5B). Thus, miR-125b over-expression promotes 
tumorigenesis in B cells in addition to myeloid cells. 
Next, we examined the stage of B cell development at which cells are sensitive to miR-
125b induced transformation; specifically, we investigated whether B cell maturation is required 
for miR-125b to induce transformation.  To this end, we over-expressed GFP+ miR-125b in 
donor BMCs from EμMT mice, which do not develop mature B cells but produce CD19+ pre-B 
cells [22]. C57Bl/6 mice were reconstituted with these cells and three months after 
transplantation, sorted GFP+ CD19+ cells were injected into sublethally irradiated mice. These 
cells became leukemic in the recipient mice, as indicated by domination of GFP+ CD19+ cells in 
the bone marrow (Fig. 5G) and induction of splenomegaly (Fig. 5H).  Thus, miR-125b can 
initiate tumorigenesis at or earlier than the pre-B cell stage of development.  Potentially, miR-
125b can directly transform pre-B cells, or miR-125b can initiate tumorigenesis at earlier stages 
of cell development with complete transformation occurring at the B cell progenitor stage.  
Nevertheless, our experiment indicates that B cell maturation is not required for miR-125b to 
induce lymphomagenesis. 
In our experiments, miR-125b ectopic over-expression initially repressed B cell genesis 
(Fig. 5A) but some cells of this lineage became cancerous later (Fig. 5B-F), leading to the 
possibility that induction of B cell leukemia may result from the accumulation of secondary 
genetic mutations involved in cellular transformation. To test this possibility, we performed 
comparative genomic hybridization microarray experiments (aCGH) of miR-125b B cancer cells 
to identify genomic alterations that might have occurred. In two independent experiments, we 
found that the B cancer cells induced by over-expression of miR-125b had an extra copy of 
chromosome 11 (Fig. 6A, Fig. S6A). This characteristic was specific to miR-125b-induced B 
cancer cells and was not found in the myeloid cancer cells (Fig. S6A).  G-band karyotyping 
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 analysis confirmed that the miR-125b-induced B cancer cells indeed harbor trisomy 11 (Fig. 
6B). No obvious inversions or translocations were identified through karyotyping. Further, the 
aCGH experiments indicated that the IgK (chromosome 6) and IgH (chromosome 12) loci had 
suffered deletions in the cancerous B cells harvested from two separate groups of mice (Fig. 
6A, Fig. S6B), suggesting that these loci had been undergo VDJ rearrangement. Thus, we 
performed flow cytometric analyses to characterize these cancer B cells further and found that 
they were CD43+ CD24+ IgM- cKit- (data not shown) with one group of cells being IgK+ IgG1+ 
(group #1) and another being predominantly IgK- IgG1- (Fig. 6C), indicating the former group of 
cells have productively rearranged their immunoglobulin loci whereas the latter did so non-
productively.  
Strikingly, in both of our independent aCGH experiments, we found that cancer B cells 
induced by miR-125b over-expression harbored genetic deficiency at the tumor suppressor 
IRF4 locus (Fig. 6A, Fig. S6A). The IRF4 genetic deletion was specific to the miR-125b-induced 
B cancer cells and was not observed in miR-125b-induced myeloid cancer cells (data not 
shown).  Quantitative PCR analysis confirmed that the translational start site of both copies of 
IRF4 was deleted in the B cell cancer samples (Fig. 6D-E), and genotyping analyses revealed 
that almost the entire IRF4 coding region (exon2-exon7, amino acids 1-366 of 450 amino acids 
full length protein) was deleted (Fig. 6D-F, Fig. S6C).  Interestingly, the population of cancer B 
cells was found to be heterogeneous with some expressing CD47 whereas others did not (Fig. 
S6D); also, individual cancer B cell samples exhibited different IRF4 genetic breaks (Fig. S6E), 
indicating that although there were different cancer clones, IRF4 deletion is ubiquitous.  The 
strong selective pressure for genetically eliminating both copies of IRF4 suggests a functional 
role of IRF4 in miR-125b-induced B cell cancer.  Indeed, multiple studies have recently 
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 demonstrated that deletion of IRF4 in mice leads to the development of B cell leukemia [12-14, 
26-29].   
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 Discussion 
 We set out to determine the mechanisms by which miR-125b induces development of 
leukemia. Relating to myeloid leukemia, we found that: (1) Myeloid cancer cells induced by miR-
125b exhibit relatively few mutational alterations; (2) miR-125b is able to promote tumorigenesis 
in vitro in a cell intrinsic manner; (3) miR-125b causes myeloproliferation by enhancing output of 
MPs from HSPC as well as promoting hyper-proliferation of MPs; (4) constitutive over-
expression of miR-125b promotes self-renewal of MPs in vitro and induces the transformed 
state in these cells; (5) miR-125b represses IRF4 expression to induce myeloid leukemia. In 
relation to miR-125b-induced B cell leukemia we found that: 1) Over-expression of miR-125b 
initially represses B cell development but constitutive long-term up-regulated expression 
provokes a highly aggressive serially transplantable B cell leukemia; 2) miR-125b can promote 
B cell leukemia by inducing tumorigenesis in cells at or earlier than the pre-B cell stage; 3) The 
miR-125b-induced B cancer cells are capable of immunoglobulin recombination; 4) Leukemic B 
cells induced by miR-125b acquire common genetic deletion of the tumor suppressor IRF4. 
Our deep-sequencing analysis indicates that miR-125b-driven myeloid cancer cells 
acquire relatively few nucleotide mutations in their exomes, suggesting that the majority of these 
cells have not acquired permanent common genetic mutations.   Thus, we speculate that 
reducing miR-125b expression might produce a regression of the myeloid tumors. In support of 
this notion, it was recently shown that survival of myeloid leukemic cells induced by miR-125a 
requires continual over-expression of this microRNA and removal of miR-125a after cancer 
development was accompanied by regression of the leukemia [30].  Further, we established that 
miR-125b functions within both HSPCs and MPs to drive a myeloproliferative disorder in vitro. 
Indeed, transplanting miR-125b over-expressing MPs could induce leukemia in recipient mice. 
These data along with the fact that miR-125b over-expressing MPs could grow indefinitely and 
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 also retain their ability to generate the entire myeloid lineage from a single cell suggests that 
miR-125b induces an abnormal self-renewal program in MPs in vitro. 
 Our data suggests that in both cases miR-125b induces myeloid and B cell leukemia by 
modulating IRF4 but through distinct mechanisms. Whereas miR-125b induces tumorigenesis in 
myeloid cells by repressing the expression of IRF4 at the mRNA and protein levels without an 
affect on its genomic content, it promotes oncogenesis in B cells by a process involving genetic 
deletion of IRF4. Thus, miR-125b represents a novel paradigm by which an oncomir might 
induce cancer development in multiple cell lineages by modulating the same signaling pathway 
but involving distinct mechanisms. In one case, the oncomir works directly to yield tumor cells; 
in the other, it blocks differentiation but a presumably spontaneous deletion then appears to 
lead to the oncogenic state. It is likely that the miR-125b-induced block of B cell differentiation is 
then overcome by the effect of the IRF4 deletion, leading to uncontrolled growth of the cells.  It 
has been shown that IRF4-/- but not IRF4+/- mice develop B cell cancer [14], indicating that 
complete ablation of IRF4 is sufficient but reduced expression of IRF4 is insufficient to drive 
tumorigenesis in B cells. Thus, we speculate that although miR-125b over-expression represses 
IRF4 expression at the mRNA level, the magnitude is not sufficient to promote tumorigenesis in 
B cells and thus require selection of cells that acquire genetic deletion of IRF4.  In addition to 
IRF4 deletion, other genes may play a role in this process as indicated by the occurrence of 
trisomy 11.  
It has also been shown that human patients with B cell leukemia have elevated 
expression of miR-125b [1, 2, 31].  There are also reports of patients that acquire genetic 
mutations at the IRF4 locus [32-35].  The increased expression of miR-125b could be caused by 
a chromosomal translocation that joins the miR-125b locus to, for instance, the immunoglobulin 
heavy chain gene regulatory elements [1, 6, 31] or it could be epigenetic.  Because of our 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
 finding that over-expression of miR-125b associates with genetic aberration at the IRF4 gene, 
we speculate that miR-125b up-regulation in human cancer patients might result in a selection 
of IRF4 genetic mutations and consequently induce lymphoblastic leukemia. In support of this 
idea, it has already been established that IRF4 deletion in mice leads to the development of B 
cell leukemia, and over-expression of IRF4 inhibits the development of B cell leukemia in mice 
using cancer models induced by c-Myc and BCR/ABL [26, 28].  Of note, our finding that the 
IRF4 tumor suppressor gene is deleted in miR-125b-induced B cancer cells suggests that 
persistent up-regulation of miR-125b might no longer be required for maintaining oncogenicity of 
these cancer cells.  Although additional experiments will be required to test this point, we 
speculate that inhibiting miR-125b will not be a suitable therapy for treating B cell leukemia 
invoked by this microRNA because permanent genetic lesions have occurred.  
 
 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
 Acknowledgements 
We thank all members of the Baltimore lab and funding sources.  NIH 1F32 CA139883-01A1 
and K99HL118754 (AYS).  Paul and Daisy Soros Fellowship and NSF Graduate Research 
Fellowship (A.A.C), and NIH 1RO1AI079243 and 1R01AI093531 (D.B).  
 
Authorship Contributions  
AYS, AAC, RS, AM, DC, CX, JK, ELL, YGF, SJ, CK, and PR performed the experiments and 
analyzed the data; AYS and DB conceived the study.  AYS, AAC, RS, AM, DC, CX, JK, ELL, SJ 
provided crucial reagents; AYS and DB wrote the manuscript; and all authors provided input for 
the manuscript. 
 
Conflict of Interest Disclosures 
The authors declare no competing financial interests.  
 
 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
  
References 
1. Chapiro, E., et al., A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-
125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia, 2010. 24(7): p. 1362-4. 
2. Tassano, E., et al., MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH 
translocation in childhood B-Cell precursor acute lymphoblastic leukemia. Genes 
Chromosomes Cancer, 2010. 49(8): p. 682-7. 
3. Zhang, H., et al., MicroRNA patterns associated with clinical prognostic parameters and CNS 
relapse prediction in pediatric acute leukemia. PLoS One, 2009. 4(11): p. e7826. 
4. Bousquet, M., et al., MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A, 2010. 
107(50): p. 21558-63. 
5. Chaudhuri, A.A., et al., Oncomir miR-125b regulates hematopoiesis by targeting the gene 
Lin28A. Proc Natl Acad Sci U S A, 2012. 109(11): p. 4233-8. 
6. Enomoto, Y., et al., Emu/miR-125b transgenic mice develop lethal B-cell malignancies. 
Leukemia, 2011. 25(12): p. 1849-56. 
7. O'Connell, R.M., et al., MicroRNAs enriched in hematopoietic stem cells differentially regulate 
long-term hematopoietic output. Proc Natl Acad Sci U S A, 2010. 107(32): p. 14235-40. 
8. Chaudhuri, A.A., et al., MicroRNA-125b potentiates macrophage activation. J Immunol, 2011. 
187(10): p. 5062-8. 
9. Ortmann, C.A., et al., Down-regulation of interferon regulatory factor 4 gene expression in 
leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids 
Res, 2005. 33(21): p. 6895-905. 
10. Schmidt, M., et al., Expression of interferon regulatory factor 4 in chronic myeloid leukemia: 
correlation with response to interferon alfa therapy. J Clin Oncol, 2000. 18(19): p. 3331-8. 
11. Klein, F., et al., Tracing the pre-B to immature B cell transition in human leukemia cells 
reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK 
deletion, and IGL gene rearrangement. J Immunol, 2005. 174(1): p. 367-75. 
12. Jo, S.H., et al., Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and 
lymphoid tumorigenesis. Blood, 2010. 116(15): p. 2759-67. 
13. Ma, S., et al., Accelerated development of chronic lymphocytic leukemia in new zealand black 
mice expressing a low level of interferon regulatory factor 4. J Biol Chem, 2013. 288(37): p. 
26430-40. 
14. Shukla, V., et al., A role for IRF4 in the development of CLL. Blood, 2013. 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
 15. Bousquet, M., et al., Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic 
syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med, 
2008. 205(11): p. 2499-506. 
16. Kumar, A., et al., Exome sequencing identifies a spectrum of mutation frequencies in advanced 
and lethal prostate cancers. Proc Natl Acad Sci U S A, 2011. 108(41): p. 17087-92. 
17. Ley, T.J., et al., DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. 
Nature, 2008. 456(7218): p. 66-72. 
18. Lilljebjorn, H., et al., Whole-exome sequencing of pediatric acute lymphoblastic leukemia. 
Leukemia, 2012. 26(7): p. 1602-7. 
19. Wang, L., et al., SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J 
Med, 2011. 365(26): p. 2497-506. 
20. Yoshida, K., et al., Frequent pathway mutations of splicing machinery in myelodysplasia. 
Nature, 2011. 478(7367): p. 64-9. 
21. Zhao, J.L., et al., MicroRNA-146a acts as a guardian of the quality and longevity of 
hematopoietic stem cells in mice. Elife, 2013. 2: p. e00537. 
22. Kitamura, D., et al., A B cell-deficient mouse by targeted disruption of the membrane exon of 
the immunoglobulin mu chain gene. Nature, 1991. 350(6317): p. 423-6. 
23. Mombaerts, P., et al., RAG-1-deficient mice have no mature B and T lymphocytes. Cell, 1992. 
68(5): p. 869-77. 
24. Gururajan, M., et al., MicroRNA 125b inhibition of B cell differentiation in germinal centers. 
Int Immunol, 2010. 22(7): p. 583-92. 
25. Malumbres, R., et al., Differentiation stage-specific expression of microRNAs in B lymphocytes 
and diffuse large B-cell lymphomas. Blood, 2009. 113(16): p. 3754-64. 
26. Acquaviva, J., X. Chen, and R. Ren, IRF-4 functions as a tumor suppressor in early B-cell 
development. Blood, 2008. 112(9): p. 3798-806. 
27. Jo, S.H. and R. Ren, IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA 
binding-independent manner. J Biol Chem, 2012. 287(3): p. 1770-8. 
28. Pathak, S., et al., IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One, 2011. 6(7): 
p. e22628. 
29. Yamamoto, M., et al., Shared and distinct functions of the transcription factors IRF4 and IRF8 
in myeloid cell development. PLoS One, 2011. 6(10): p. e25812. 
30. Guo, S., et al., Complex oncogene dependence in microRNA-125a-induced myeloproliferative 
neoplasms. Proc Natl Acad Sci U S A, 2012. 109(41): p. 16636-41. 
31. Sonoki, T., et al., Insertion of microRNA-125b-1, a human homologue of lin-4, into a 
rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute 
lymphoblastic leukemia. Leukemia, 2005. 19(11): p. 2009-10. 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
 32. Di Bernardo, M.C., et al., A genome-wide association study identifies six susceptibility loci for 
chronic lymphocytic leukemia. Nat Genet, 2008. 40(10): p. 1204-10. 
33. Lan, Q., et al., Genetic susceptibility for chronic lymphocytic leukemia among Chinese in Hong 
Kong. Eur J Haematol, 2010. 85(6): p. 492-5. 
34. Slager, S.L., et al., Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer 
Epidemiol Biomarkers Prev, 2010. 19(4): p. 1098-102. 
35. Havelange, V., et al., IRF4 mutations in chronic lymphocytic leukemia. Blood, 2011. 118(10): 
p. 2827-9. 
 
 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
 Figure Legends 
  Figure 1: Features of miR-125b-induced myeloid cancer cells. 
A) Leukemic cells from MG-125b are serially transplantable. Cells from MG and MG-125b mice 
were harvested three to six months after bone marrow reconstitution. 200K GFP+ splenic cells 
(black dotted line) or 400-1000K GFP+ BMCs (red line) from MG-125b mice were transferred 
into secondary sublethally irradiated C57bl/6 recipients. Two million GFP+ BMCs from the 
secondary mice were injected into tertiary non-irradiated C57bl/6 recipients (orange line 
indicated as ‘no irradiation’). Death point of the recipients (at least four mice per group) were 
recorded when found dead or moribund. B) Myeloid cancer cells induced by miR-125b over-
expression were harvested and subjected to exome deep-sequencing analysis.  Every exon 
was sequenced an average of 50 times.  The sequencing data sets were filtered on a 0.1% 
false positive discovery rate and cancer-associated mutations were obtained by excluding those 
that were identified in normal non-cancerous mice. Plot shows the number of cancer-associated 
exonic mutations identified in each of the three independent experiments. C) Donor BMCs from 
C57bl/6, Rag1-/-, and EμMT (B6.129S2-Ighmtm1Cgn/J) mice were transduced with MG-125b 
retroviruses, which encode for miR-125b and GFP expression. As control, donor BMCs from 
C57bl/6 animals were transduced with empty MG retroviruses, which encode for GFP. BMCs 
were transplanted into lethally irradiated C57bl/6 recipients, and the blood of the mice was 
subjected to flow cytometric analyses three months after reconstitution. D) The survival curve of 
the mice described in panel C is shown (three mice per group). Mice were considered dead 
when they became moribund or found dead.  
 
Figure 2: Over-expressing miR-125b in BMCs induces myelo-proliferative disorder in 
vitro.  A) Hematopoietic-stem and progenitor cell (HSPC)-enriched BMCs, which were obtained 
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 by injecting C57bl/6 mice with 5-fluorouracil, were transduced with MG control or MG-125b 
retroviruses.  Equal numbers of BMCs were cultured in 50ng/mL SCF, 50ng/mL IL-6, and 
25ng/mL IL-3.  After 5 days, the total number of myeloid cells (CD11b+) cells was determined by 
flow cytometry. B) MG control or miR-125b over-expressing HSPC-enriched cells were 
expanded at same starting density in 50ng/mL SCF.  Cells were counted by flow cytometry. C) 
Equal numbers of HSPC-enriched cells transduced with MG or miR-125b over-expression 
cassette were expanded in 50ng/mL SCF. The density of Lin- Sca1- cKit+ cells after four days 
was determined by flow cytometry. D) Equal numbers of MG control or miR-125b over-
expressing BMCs were cultured in 20ng/mL GMCSF to induce differentiation into dendritic cells. 
The number of dendritic cells was determined by flow cytometry six days after culture. E) MG or 
miR-125b transduced BMCs were cultured in 50ng/mL SCF. When the miR-125b over-
expressing cells were confluent between 4-8 days after plating, the cells were re-seeded at a 
starting density of 20K per mL. The X-axis represents the passage number, and the Y-axis 
represents the cell density.  Panels A-E are representative of at least two independent 
experiments. F) MiR-125b over-expressing BMCs were cultured and expanded in vitro. One 
million GFP+ cells were injected into sublethally irradiated C57bl/6 mice. Two months post-
transplantation, recipient blood was subjected to flow cytometric analysis to determine 
engraftment of GFP+ cells. The pictures of G) spleen and H) femur are representative examples 
of these organs taken from moribund miR-125b transduced mice (right panel) and age-matched 
C57bl/6 controls (left panel). Representative of six mice.  
 
Figure 3: Effect of over-expressing miR-125b in HSPCs and MPs.  A) Equal numbers of MG 
or MG-125b transduced Lin- cKit+ Sca1+ HSPCs were cultured, and the cell density was 
determined using flow cytometry. Two-way ANOVA was used to obtain P values. The number of 
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 B) Lin- cKit+ Sca1+ HSPCs and C) Lin- cKit+ Sca1- MPs was determined by flow cytometry six 
days after culture.  D) The ratio of MPs to HSPCs was calculated and plotted. Two independent 
experiments were performed. F) The density of myeloids (Cd11b+), granulocytes (GR1+) or non-
granulocytic myeloids (CD11b+ GR1-) cells after growing miR-125b over-expressing MPs was 
determined by flow cytometry ten days later. Two independent experiments performed. G) 
Sorted MG or miR-125b transduced Lin- cKit+ Sca1- MPs were cultured and passaged similarly 
as described in Fig. 2E legend. H) Sublethally irradiated C57bl/6 recipients were injected with 
common myeloid progenitors sorted from MG-125b mice. Wright stain of the blood was 
performed when the recipients were moribund.  I) The spleen and J) femur were harvested and 
imaged when the mice were moribund and sacrificed. Representative of four mice. Control mice 
represent recipient mice injected with BMCs from MG mice.  
 
Figure 4: Rescued expression of IRF4 inhibits miR-125b-induced myeloid leukemia.  A) 
IRF4 inhibits miR-125b-induced hyper-proliferation in vitro. Control cells correspond to MG 
infected BMCs.  BMCs were transduced with retroviruses that encode miR-125b and HcRed.  
These cells were then transduced with MG or MIG-IRF4 retroviruses, which co-expresses GFP 
and IRF4.  HcRed+ GFP+ cells were sorted, and 20K cells per mL of cells were plated. The cell 
number was determined three days later. Representative of three experiments. B) BMCs were 
transduced with retroviruses that encode miR-125b and mCherry. These cells were then 
infected with MG or MIG-IRF4 viruses. Shown are flow cytometric plots of these cells and 
infection efficiency before transplantation into mice. Plots show cells over-expressing miR-125b 
in the X-axis (mCherry+) and either GFP+ or GFP+ IRF4-over-expressing cells in the Y-axis. C) 
BMCs described in panel B were transplanted into recipient C57bl/6 mice.  One month after 
transplantation, the peripheral blood of the recipient mice was analyzed by flow cytometry. The 
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 left and right panel represents the blood of recipient mice transplanted with BMCs co-infected 
with miR125b-mCherry with GFP vector and miR125b-mCherry with IRF4-GFP vector, 
respectively. Representative of four mice. D) Recipient mice were transplanted with donor 
BMCs that over-express miR-125b alone or along with restored IRF4 expression mice. The 
peripheral blood of the recipient mice (greater than six mice per group) was analyzed by flow 
cytometry. Plot displays the Cd11b+ myeloid cell count three months after transplantation of 
donor cells. Control mice represent normal healthy C57bl/6 mice. P value obtained through 
Mann Whitney T test. E) The percent splenic Cd11b+ myeloid was determined using flow 
cytometry ~3 months after cell transplantation. G) Representative images of the femur and tibia 
of the corresponding recipient mice are shown.  
 
 Figure 5: MiR-125b induces tumorigenesis in pre-B cells.  A) MG and MG-125b were bled 
12 weeks after bone marrow reconstitution. The figure represents the percent of B cells (CD19+) 
within the GFP+ gated population in the peripheral blood of these mice (at least three mice per 
group).  P value was calculated by Student’s T test. B) GFP+ CD19+ B cells were sorted from 
MG-125b mice 4-6 months after bone marrow reconstitution. 35-52K CD19+ B cells were 
transplanted into sublethally irradiated mice. The figure shows the flow cytometric analysis of the 
secondary recipient mice (bone marrow) six weeks after transplantation. Representative of eight 
mice. C) The figure shows the survival of curve of the secondary recipient mice transplanted with 
GFP+ CD19+ cells from MG-125b mice (eight mice) or total BMCs from MG mice (six mice). D) 
Wright stain was performed from the blood of recipient mice injected with miR-125b over-
expressing CD19+ cells. The dark purple cells represent leukocytes.  The smaller cells with 
central pallor are red blood cells. E) Some recipients of miR-125b over-expressing CD19+ cells 
develop lymphomas. Lymphomas shown at the superficial cervical (top blue arrow) and inguinal 
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 lymph node sites (side blue arrow). The normal mouse shown is a healthy C57bl/6 mouse. F) 
Left panel: The spleen weight of the recipient mice transplanted with GFP+ CD19+ cells (denoted 
as “miR-125b CD19+) from MG-125b mice or total BMCs from MG animals were obtained 4-6 
months after transplantation. Six mice per group. Right panel: Representative images of spleens 
harvested from normal C57bl/6 control and miR-125b CD19 transplanted mice 6-months post 
transplant. G) MiR-125b induces pre-B cell cancer. 10K sorted GFP+ CD19+ cells harvested from 
mice reconstituted with miR-125b over-expressing EμMT BMCs were injected into sublethally 
irradiated secondary C57bl/6 recipients.  Bone marrow of the secondary recipient harvested 
when the mice became moribund, and figure shows flow cytometric plot of the leukocyte 
population of the bone marrow. H) Spleen weights of the secondary recipients described in panel 
H are shown (four mice). The controls signify spleen weight from secondary recipients injected 
with cells from MG reconstituted mice (eight mice). P value was calculated by Student’s T test.  
 
Figure 6: Deletion of IRF4 in miR-125b cells. A) Analysis of genetic mutations in cancer B 
cells through comparative genomic hybridization microarray (aCGH). Genomic DNA harvested 
from sorted miR-125b over-expressing GFP+ CD19+ cancer B cells was subjected to aCGH 
analysis. Genomic DNA from normal C57bl/6 mice of the same gender (female) was used as 
controls. The figure represents the relative amount of genetic content of the cancer sample 
versus the C57bl/6 control (plotted as ratio in Y axis). A genomic region was considered different 
between the samples if 3 consecutive probes exhibited different signal intensities in the 
microarray. Regions highlighted in green and orange indicate genomic areas in which the cancer 
cells have higher and lower DNA content, respectively. The other aCGH analysis is displayed in 
Fig. S6A.  B) G-band karyotyping of miR-125b-induced cancer B cells. Trisomy 11 is highlighted 
in red box. C) Flow cytometric analysis of cancer B cells. Sorted GFP+ CD19+ cells isolated from 
For personal use only.on July 14, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
 independent groups of MG-125b mice were transplanted into recipient mice. Upon cancer 
development, the bone marrow of these mice (highlight in red) was analyzed by flow cytometry.  
The plot shows the samples within the CD19+ gated population. The sample overlaid in black 
represents total BMCs harvested from healthy control C57bl/6 mice. Group #1 and group #2 
corresponds to the aCGH samples displayed in Fig. 6A and Fig. S6A respectively.  D) IRF4 
locus and genotyping primer sequences. IRF4 locus is shown with exons represented as solid 
bars.  ‘Start,’ ‘ex,’ and ‘int’ signifies translation start site, exon, and intron respectively. The red 
bars represent the PCR product amplified by the primers used for genotyping in panel E-F and 
Fig. S6E.  E) Quantitative PCR analysis of IRF4 locus. The relative amount of genomic DNA 
from miR-125b-induced cancer B cells were quantified by qPCR and normalized to control 
Hsp70 locus.  The control samples are genomic DNA harvested from normal C57bl/6 mice. The 
PCR reaction amplifies a region spanning the translational start site (denoted as ‘start’ in panel 
C). F) Genomic DNA from miR-125b-induced cancer B cells was subjected to genotyping 
analysis. Exon2 (ex2), exon4 (ex4), and exon6 (ex6) of IRF4 were assessed. Bach1 locus was 
used as positive control.  Samples #3-4 and #5-6 correspond to miR-125b-induced cancer B 
cells harvested from mice originating from group #1 and group #2 described in Fig. 5G, 
respectively. The agarose gel images of the PCR reactions are displayed. 
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Page 1 of 1            WiCell Research Institute  WiCell Cytogenetics Lab  PO Box 7365  Madison Wisconsin  53707-7365 10/19/2011 
                                                       Chromosome Analysis Report: 006722 
 
Report Date: October 19, 2011 
 
Cell Line:    Mouse #23-CD19+                                                              
Passage #:    N/A  
Date of Sample:    10/13/2011                                                 
Date Completed:    10/19/2011       
 
Specimen:    Mouse                                                 
Cell Line Gender: Female
Reason for Testing:    To determine whether 
primary cancer cells harvested from mice 
have chromosomal abnormalities  
Investigator:    Alex So, California Institute 
for Technology
Results:    41,XX,+11 
 
 
Cell:    S01-10                                                           
Slide:   1-LMI(4)KARYOTYPE 
Slide Type:    Karyotyping                                                       
 
 
# of Cells Counted: 6  
# of Cells Karyotyped: 2    
# of Cells Analyzed: 2                
Band Level: ~230                
Interpretation:    
This is an abnormal karyotype with trisomy 11 in all cells examined.  Trisomy 11 is a recurrent 
finding in mouse stem cell lines. 
 
This is a limited, but informative analysis, based on examination of six cells. Standard 
analysis requires examination of twenty cells. All available metaphase cells were evaluated. 
Completed by Kim Leonhard, CG(ASCP), on 10/19/2011 
Reviewed and interpreted by Karen Dyer Montgomery, PhD, FACMG, on 10/19/2011
A signed copy of this report is available upon request. 
 
Date:__________________________ 
Sent By:____________________________ 
Sent To:_______________________ 
QC Review By: ______________________   
 
Limitations: This assay allows for microscopic visualization of numerical and structural chromosome abnormalities.  The size of structural abnormality 
that can be detected is >3-10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is 
defined as the number of G-bands per haploid genome. It is documented here as “band level”, i.e., the range of bands determined from the four 
karyograms in this assay.  Detection of heterogeneity of clonal cell populations in this specimen (i.e.,mosaicism) is limited by the number of metaphase 
cells examined, documented here as “# of cells counted”.  
 
This assay was conducted solely for listed investigator/institution. The results may not be relied upon by any other party without the prior written consent 
of the Director of the WiCell Cytogenetics Laboratory.  The results of this assay are for research use only.  If the results of this assay are to be used for 
any other purpose, contact the Director of the WiCell Cytogenetics Laboratory. 
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